New drug combo may reduce chronic transplant complications in blood cancer patients

This study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The trial enrolled 43 participants and compared the new drug combo to standard care. The main goal was to see if fewer patients developed moderate or severe chronic GVHD one year after transplant.